For ABHD2, mRNA expression was significantly lower in ovarian cancer than that in serous borderline tumors (SBT) (p=0.001; GSE9891, p=0.006; GSE2109, Figure 2a). This evidence concerns the gene ABHD2 and ovarian carcinoma.